Weekly round-up: Novo Nordisk Foundation announces funding milestone, breakthrough AI results revealed
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart.
Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year
Following its 100th anniversary in 2024, the Novo Nordisk Foundation on Thursday announced that it was a milestone year, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving people’s health and the sustainability of society and the planet.
The Foundation’s support spanned a diverse array of initiatives, both within Denmark and globally, including projects focused on the green transition, advancement of new technologies, cardiometabolic diseases, and antimicrobial resistance.
Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform
Commit Biologics, a pioneer in the activation of the complement system to treat cancer and autoimmune disease, on Tuesday announced a €5.5m extension to its seed financing.
The contribution from new investor Korys brings the total seed financing raised since Commit’s launch to €21.5m. Commit emerged from stealth last May, having raised €16m from Novo Holdings and Bioqube Ventures.
BrightHeart unveils breakthrough AI results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy meeting, revolutionizing prenatal care
BrightHeart, a Sofinnova Partners portfolio company and global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and concurrent sessions on January 30th at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, held in Aurora, Colorado.
Optimum TV
Optimum TV’s latest guest Dale Raine, Global Co-head of Biopharma at Lazard shares his thoughts on the state of M&A, the appetite for IPOs, what’s hot and what’s not in biotech, plus top tips for firms looking to do deals.
Watch our insightful interview and reshare Dale’s insights with your network now!
Optimum’s Hot Topics
Sector Moves
Check out the latest moves in the life sciences sector with our monthly round-up of new funds and the biggest job changes, including analysts, bankers, and healthcare journalists.
That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe on LinkedIn today so you never miss an edition.